Alex Zhavoronkov
Founder and CEO of Insilico Medicine
Alex Zhavoronkov is the founder and CEO of Insilico Medicine, a company that uses artificial intelligence to find drug targets and design drug candidates, including treatments for fibrosis and diseases of aging. He writes and speaks about longevity research and aging biomarkers, and has said he takes a GLP-1 drug for longevity.
Updated November 1, 2026 · 1 experiment
What Alex Zhavoronkov has tried
1 experiment we can source: 1 kept. Trying something is not recommending it; each entry says which.
Kept
GLP-1 drugsDrugs
Dates not stated · Does not recommend it to others
Takes a GLP-1 drug for longevity at a full dose despite normal weight, while saying the longevity evidence is not yet complete.
“GLP-1s do not have a full body of evidence to demonstrate the longevity effect”
The Scientist, Can GLP-1 drugs extend lifespan? The jury is still out (2026) · Status checked November 1, 2026 · Suggest a correction